Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myra Robinson

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cancer Medicine|February 12, 2017
The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long-term community-based cancer center experienceJeffrey S Kneisl, Chad Ferguson, Myra Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2020
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based RegimensJai N Patel, Myra Robinson, Megan Jagosky, et al.
The Pharmacogenomics Journal|November 5, 2023
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosingJai N Patel, Myra Robinson, Sarah A Morris, et al.
Blood Cancer Journal|November 10, 2018
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myelomaShebli Atrash, Myra Robinson, Daniel Slaughter, et al.
Practical Radiation Oncology|July 5, 2023
Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 TrialJohn H Heinzerling, Olga V Pen, Myra Robinson, et al.
JCO Oncology Practice|June 16, 2022
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic MalignancyThomas G Knight, Melissa Aguiar, Myra Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.
European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.
Ejhaem|July 18, 2022
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myelomaDavid M Foureau, Manisha Bhutani, Myra Robinson, et al.
Clinical Genitourinary Cancer|May 2, 2024
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With ChemotherapyLandon C Brown, Myra Robinson, Michael McCormack, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer Medicine|February 12, 2017
The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long-term community-based cancer center experienceJeffrey S Kneisl, Chad Ferguson, Myra Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2020
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based RegimensJai N Patel, Myra Robinson, Megan Jagosky, et al.
The Pharmacogenomics Journal|November 5, 2023
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosingJai N Patel, Myra Robinson, Sarah A Morris, et al.
Blood Cancer Journal|November 10, 2018
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myelomaShebli Atrash, Myra Robinson, Daniel Slaughter, et al.
Practical Radiation Oncology|July 5, 2023
Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 TrialJohn H Heinzerling, Olga V Pen, Myra Robinson, et al.
JCO Oncology Practice|June 16, 2022
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic MalignancyThomas G Knight, Melissa Aguiar, Myra Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.
European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.
Ejhaem|July 18, 2022
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myelomaDavid M Foureau, Manisha Bhutani, Myra Robinson, et al.
Clinical Genitourinary Cancer|May 2, 2024
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With ChemotherapyLandon C Brown, Myra Robinson, Michael McCormack, et al.
Pageof 3